Heirloom Wealth Management Has $7.26 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Heirloom Wealth Management lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,835 shares of the pharmaceutical company’s stock after purchasing an additional 384 shares during the period. Vertex Pharmaceuticals accounts for 2.8% of Heirloom Wealth Management’s holdings, making the stock its 13th biggest holding. Heirloom Wealth Management’s holdings in Vertex Pharmaceuticals were worth $7,257,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Venturi Wealth Management LLC grew its position in Vertex Pharmaceuticals by 1.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after purchasing an additional 24 shares in the last quarter. Arthur M. Cohen & Associates LLC grew its position in Vertex Pharmaceuticals by 3.2% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after purchasing an additional 25 shares in the last quarter. Baystate Wealth Management LLC grew its position in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 25 shares in the last quarter. Cooper Financial Group boosted its stake in Vertex Pharmaceuticals by 1.0% in the third quarter. Cooper Financial Group now owns 3,020 shares of the pharmaceutical company’s stock valued at $1,050,000 after acquiring an additional 29 shares during the last quarter. Finally, Arjuna Capital boosted its stake in Vertex Pharmaceuticals by 0.7% in the third quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock valued at $1,521,000 after acquiring an additional 29 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling

In related news, Chairman Jeffrey M. Leiden sold 2,656 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $419.51, for a total value of $1,114,218.56. Following the transaction, the chairman now owns 27,644 shares in the company, valued at approximately $11,596,934.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Jeffrey M. Leiden sold 2,656 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $419.51, for a total transaction of $1,114,218.56. Following the completion of the transaction, the chairman now owns 27,644 shares in the company, valued at approximately $11,596,934.44. The disclosure for this sale can be found here. Insiders have sold a total of 12,381 shares of company stock worth $5,203,249 in the last 90 days. 0.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on VRTX shares. Royal Bank of Canada boosted their target price on shares of Vertex Pharmaceuticals from $397.00 to $420.00 and gave the company a “sector perform” rating in a research note on Tuesday, February 6th. StockNews.com upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 12th. Evercore ISI raised shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective for the company in a report on Thursday, April 11th. UBS Group cut their price objective on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Canaccord Genuity Group downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and raised their price objective for the stock from $332.00 to $379.00 in a report on Wednesday, January 24th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $429.45.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX traded up $0.80 during mid-day trading on Friday, reaching $394.28. 1,342,016 shares of the company were exchanged, compared to its average volume of 1,246,165. Vertex Pharmaceuticals Incorporated has a 52 week low of $316.43 and a 52 week high of $448.40. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $101.91 billion, a PE ratio of 28.39, a PEG ratio of 1.85 and a beta of 0.35. The company’s 50 day moving average price is $413.60 and its 200 day moving average price is $397.06.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. The company had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same quarter last year, the company earned $3.33 EPS. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.